文献速递泌尿男性生殖肿瘤

多西他赛联合放疗与雄激素剥夺治疗高危非转移性前列腺癌的随机试验

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
PubMed 文献 · J Clin Oncol · 2021-07-01

这项前瞻性随机试验纳入350例T1c-4N0M0不利风险前列腺癌患者,比较ADT+放疗联合或不联合多西他赛的疗效。PSA<4 ng/mL亚组中多西他赛可能通过降低前列腺癌特异性死亡延长总生存。

要点

  • 多西他赛联合ADT+放疗未显著改善不利风险前列腺癌患者总生存。
  • 多西他赛显著降低放疗诱导癌症发生率(10年0.61% vs 4.90%)。
  • PSA<4 ng/mL亚组中多西他赛可能降低前列腺癌特异性死亡并延长总生存。

核心结论

  • 在不利风险前列腺癌患者中,ADT+放疗联合多西他赛未显著延长总生存,但降低了放疗诱导癌症发生率。
  • PSA<4 ng/mL亚组中加用多西他赛可能通过减少前列腺癌特异性死亡延长总生存。

研究设计与样本

  • 前瞻性随机试验,2005年9月21日至2015年1月13日随机分配350例T1c-4N0M0不利风险前列腺癌患者1:1接受ADT+放疗联合多西他赛或单纯ADT+放疗。
  • 多西他赛方案为放疗前每3周60 mg/m2共3周期,放疗期间每周20 mg/m2。
  • 主要终点为总生存,并评估放疗诱导癌症发生率及PSA亚组(<4、>20 vs 4-20 ng/mL)的治疗效应异质性。

主要发现

  • 中位随访10.2年,89例(25.43%)死亡,其中42例(47.19%)死于前列腺癌。
  • PSA<4 ng/mL与4-20 ng/mL亚组间总生存治疗效应显著不同,校正风险比分别为0.27和1.51。
  • PSA<4 ng/mL亚组中多西他赛组前列腺癌特异性死亡为0.00% vs 28.57%。

关键数值与推荐

  • 多西他赛方案:放疗前每3周60 mg/m2共3周期,放疗期间每周20 mg/m2。
  • PSA<4 ng/mL亚组总生存校正HR 0.27,PSA 4-20 ng/mL亚组校正HR 1.51。
  • PSA<4 ng/mL亚组前列腺癌特异性死亡:多西他赛组0.00% vs 对照组28.57%。

临床怎么用

  • 对于不利风险非转移性前列腺癌,ADT+放疗基础上加用多西他赛不应以延长总生存为主要目的常规推荐。
  • 多西他赛可能降低放疗诱导癌症风险,可作为个体化决策时与患者讨论的潜在获益。
  • PSA<4 ng/mL的亚组患者可能从多西他赛中获益,需进一步验证后考虑个体化使用。

局限性

  • 研究样本量350例,可能不足以检测总生存的微小差异。
  • PSA亚组分析为探索性,交互作用检验结果需谨慎解读。
  • 随访10.2年,放疗诱导癌症的长期风险仍需更长时间观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist. METHODS: Between September 21, 2005, and January 13, 2015, we randomly assigned 350 men 1:1 with T1c-4N0M0 unfavorable-risk PC to receive radiation therapy (RT) and androgen deprivation therapy (ADT) plus docetaxel (60 mg/m2 once every 3 weeks for three cycles before RT and 20 mg/m2 once weekly during RT) versus ADT + RT. We evaluated the treatment effect of adding docetaxel to ADT + RT on the primary end point of overall survival (OS) and the incidence of RT-induced cancers and explored whether the impact of the treatment effect on OS differed within prostate-specific antigen (PSA) subgroups (< 4, > 20 v 4-20 ng/mL) using the interaction test for heterogeneity adjusted for age and PC prognostic factors. RESULTS: After a median follow-up of 10.2 years, 89 men died (25.43%); of these, 42 from PC (47.19%). Although OS was not significantly increased in the docetaxel arm (the restricted mean survival time over 10 years was 9.11 v 8.82 years; P = .22), significantly fewer RT-induced cancers were observed (10-year estimates: 0.61% v 4.90%; age-adjusted hazard ratio of 0.13; 95% CI, 0.02 to 0.97; P = .046). The treatment effect of adding docetaxel to ADT + RT on OS significantly differed in men with a PSA < 4 ng/mL versus 4-20 ng/mL (adjusted hazard ratio: 0.27 and 1.51, respectively) because of less PC-specific mortality on the docetaxel arm (0.00% v 28.57%) among men with PSA < 4 ng/mL. CONCLUSION: Adding docetaxel to ADT + RT did not prolong OS in men with unfavorable-risk PC, but decreased RT-induced cancer incidence, and may prolong OS in the subgroup of men with a PSA < 4 ng/mL by reducing PC-specific mortality.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. D'Amico AV, Xie W, McMahon E, et al. Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. J Clin Oncol. 2021. PMID: 34197181. doi:10.1200/JCO.21.00596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。